Thinking about taking Mounjaro for one month only?

Why the first month is designed for adjustment, not results

The licensed Mounjaro schedule opens at 2.5mg once weekly for four weeks. That dose exists for a specific reason: tirzepatide works on two gut-hormone receptors simultaneously (GLP-1 and GIP) and that dual action can bring noticeable nausea, particularly in the first days after each injection. The starter dose is the body's settling-in period. As the NHS tirzepatide information page notes, the dose is then increased gradually, typically in four-week steps, under prescriber guidance.

So someone who takes Mounjaro for exactly one month will complete week four still at 2.5mg, before any dose increase has happened. That is not a flaw, it is how the medicine is designed to work safely. The practical upshot is that a single month captures the tolerability phase almost entirely. If you are weighing up whether taking Mounjaro for just one month is a realistic option, that page walks through what it actually involves from a clinical standpoint. Whether you move to 5mg, continue, or stop is a clinical decision, not a commercial one.

People sometimes arrive at this question for very practical reasons: they ordered on payday, they have a holiday coming up, or they simply want to try one pen before committing further. Those are understandable starting points, and a prescriber can help you think through the timing properly rather than guessing.

What the trial data says about short versus sustained use

The SURMOUNT-1 trial (2,539 adults with obesity and no diabetes, followed for 72 weeks) is the foundational evidence for Mounjaro's weight-management licence. Average body-weight reduction reached around 20–21% at the 15mg maintenance dose, but that figure accumulated over many months of escalating treatment, not in the first four weeks. The published trial paper in the New England Journal of Medicine makes the trajectory clear: weight loss was ongoing and progressive through the dose-escalation period, with the steepest relative decline coming after participants reached higher maintenance doses.

There is no published sub-analysis from SURMOUNT-1 isolating outcomes at exactly four weeks, which means citing a specific figure for one-month-only use would be misleading. What is documented, from trial extension and discontinuation data across GLP-1 programmes, is that weight regain tends to follow stopping, a pattern NICE's appraisal of tirzepatide acknowledges in its guidance on reviewing continuation. If you are exploring what realistic weight loss in the first month looks like, that page sets out the evidence without overstatement.

The honest answer is that one month on Mounjaro gives your body a careful introduction to the medicine. It does not give you a full picture of what tirzepatide can do.

Can you legally stop after one month, and should you?

Yes, you can stop. Mounjaro is not a medicine that requires tapering the way some treatments do, and there is no clinical contraindication to stopping after a single pen. What the evidence and prescriber guidance both emphasise is that stopping is worth a conversation rather than a unilateral decision, partly because of the documented weight regain trajectory, and partly because your prescriber will want to review whether stopping is appropriate given your clinical goals.

Whether a single month of treatment makes clinical sense for you depends on factors your prescriber will assess: your BMI, any weight-related conditions, how you tolerated the starter dose, and what you are trying to achieve. NICE's recommendation for tirzepatide is framed around continuing treatment only if clinically appropriate, and reviewing at six months if weight loss is below 5% on the highest tolerated dose. That framing assumes ongoing treatment, not a four-week trial.

For a fuller picture of what private Mounjaro treatment costs across a realistic duration, that page sets out the pricing context honestly. Cost is a real factor in how long people stay on treatment, and a transparent conversation about it is part of what our prescribers do at every review.

What stopping after one month means in practice

If you stop after week four, tirzepatide clears your system over the following weeks; there is no abrupt physiological event. Appetite typically returns toward its pre-treatment baseline. For some people that is manageable with the lifestyle habits built alongside treatment; for others, the return of appetite is rapid and uncomfortable. The clinical evidence for GLP-1 medicines as a class is consistent on this point: the benefits are sustained by continued treatment, and the degree of regain after stopping is proportional to the weight lost.

That is not a reason to feel pressured into staying on treatment longer than you want or can afford. It is a reason to go into a one-month course with realistic expectations. Our prescribers will discuss all of this with you before dispensing anything, and their review is not a formality, it is where the clinical picture gets built. You can read more about what people typically experience in their first month on Mounjaro, and about the broader weight-loss treatment options available if tirzepatide is not the right fit for you right now.

Mounjaro is a prescription-only medicine. A GPhC-registered Independent Prescriber at nume reviews every consultation personally. If you have questions before you decide, our support team is available seven days a week, and our FAQs cover the practicalities in more detail.